MADISON, Wis., Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2023 financial results after the close of the U.S. financial markets on November 1, 2023. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
Third quarter 2023 webcast & conference call details
Date: | Wednesday, November 1, 2023 |
Time: | 5 p.m. ET |
Webcast: | The live webcast can be accessed at www.exactsciences.com |
Telephone: | Domestic callers, dial 888-330-2384 |
International callers, dial +1 240-789-2701 | |
Access code for both domestic and international callers: 4437608 |
An archive of the webcast will be available at www.exactsciences.com. A replay of the conference call will be available by calling 800-770-2030 domestically or +1 647-362-9199 internationally. The access code for the replay of the call is 4437608. The webcast, conference call, and replay are open to all interested parties.
About Exact Sciences Corp.
A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.
Contact:
Megan Jones
Exact Sciences Corp.
This email address is being protected from spambots. You need JavaScript enabled to view it.
608-535-8815
| Last Trade: | US$61.69 |
| Daily Change: | 1.59 2.65 |
| Daily Volume: | 2,472,883 |
| Market Cap: | US$11.400B |
November 25, 2024 November 13, 2024 November 05, 2024 October 27, 2024 October 04, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
